{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:44:39Z","timestamp":1789764279259,"version":"4.0.1"},"reference-count":65,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The spinocerebellar ataxias (SCA) comprise a group of inherited neurodegenerative diseases. Machado\u2013Joseph Disease (MJD) or spinocerebellar ataxia 3 (SCA3) is the most common autosomal dominant form, caused by the expansion of CAG repeats within the ataxin-3 (ATXN3) gene. This mutation results in the expression of an abnormal protein containing long polyglutamine (polyQ) stretches that confers a toxic gain of function and leads to misfolding and aggregation of ATXN3 in neurons. As a result of the neurodegenerative process, SCA3 patients are severely disabled and die prematurely. Several screening approaches, e.g., druggable genome-wide and drug library screenings have been performed, focussing on the reduction in stably overexpressed ATXN3(polyQ) protein and improvement in the resultant toxicity. Transgenic overexpression models of toxic ATXN3, however, missed potential modulators of endogenous ATXN3 regulation. In another approach to identify modifiers of endogenous ATXN3 expression using a CRISPR\/Cas9-modified SK-N-SH wild-type cell line with a GFP-T2A-luciferase (LUC) cassette under the control of the endogenous ATXN3 promotor, four statins were identified as potential activators of expression. We here provide an overview of the high throughput screening approaches yet performed to find compounds or genomic modifiers of ATXN3(polyQ) toxicity in different SCA3 model organisms and cell lines to ameliorate and halt SCA3 progression in patients. Furthermore, the putative role of cholesterol in neurodegenerative diseases (NDDs) in general and SCA3 in particular is discussed.<\/jats:p>","DOI":"10.3390\/ijms25073984","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T08:42:34Z","timestamp":1712133754000},"page":"3984","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Spinocerebellar Ataxia Type 3 Pathophysiology\u2014Implications for Translational Research and Clinical Studies"],"prefix":"10.3390","volume":"25","author":[{"given":"Fabian","family":"Stahl","sequence":"first","affiliation":[{"name":"German Centre for Neurodegenerative Disease (DZNE), 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd O.","family":"Evert","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Neurodegenerative Diseases, University of Bonn, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Han","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Neurodegenerative Diseases, University of Bonn, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Breuer","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Neurodegenerative Diseases, University of Bonn, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-0790","authenticated-orcid":false,"given":"Ullrich","family":"W\u00fcllner","sequence":"additional","affiliation":[{"name":"German Centre for Neurodegenerative Disease (DZNE), 53127 Bonn, Germany"},{"name":"Departments of Neurology and Neurodegenerative Diseases, University of Bonn, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-019-0074-3","article-title":"Spinocerebellar ataxia","volume":"5","author":"Klockgether","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jsb.2017.09.006","article-title":"Polyglutamine expansion diseases: More than simple repeats","volume":"201","author":"Silva","year":"2018","journal-title":"J. Struct. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0896-6273(00)80943-5","article-title":"Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3","volume":"19","author":"Paulson","year":"1997","journal-title":"Neuron"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/hmg\/8.7.1169","article-title":"High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells","volume":"8","author":"Evert","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ng1194-221","article-title":"CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1","volume":"8","author":"Kawaguchi","year":"1994","journal-title":"Nat. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0378-1119(03)00706-6","article-title":"The human MJD gene: Genomic structure and functional characterization of the promoter region","volume":"314","author":"Schmitt","year":"2003","journal-title":"Gene"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10048-009-0216-y","article-title":"Increased transcript diversity: Novel splicing variants of Machado-Joseph disease gene (ATXN3)","volume":"11","author":"Bettencourt","year":"2010","journal-title":"Neurogenetics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1750-3639.1998.tb00193.x","article-title":"An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients","volume":"8","author":"Schmidt","year":"1998","journal-title":"Brain Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"192.e5","DOI":"10.1016\/j.neurobiolaging.2016.12.014","article-title":"Alteration of methylation status in the ATXN3 gene promoter region is linked to the SCA3\/MJD","volume":"53","author":"Wang","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.ymthe.2017.01.021","article-title":"Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease","volume":"25","author":"Carmona","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/2211536607666180821162403","article-title":"Upregulation of miR-25 and miR-181 Family Members Correlates with Reduced Expression of ATXN3 in Lymphocytes from SCA3 Patients","volume":"8","author":"Krauss","year":"2019","journal-title":"Microrna"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.jmb.2019.01.019","article-title":"The Role of MicroRNAs in Spinocerebellar Ataxia Type 3","volume":"431","author":"Krauss","year":"2019","journal-title":"J. Mol. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"McLoughlin, H.S., Moore, L.R., and Paulson, H.L. (2020). Pathogenesis of SCA3 and implications for other polyglutamine diseases. Neurobiol. Dis., 134.","DOI":"10.1016\/j.nbd.2019.104635"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/sj.emboj.7601043","article-title":"An arginine\/lysine-rich motif is crucial for VCP\/p97-mediated modulation of ataxin-3 fibrillogenesis","volume":"25","author":"Boeddrich","year":"2006","journal-title":"EMBO J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"18392","DOI":"10.1074\/jbc.M117.806281","article-title":"Interaction between the AAA(+) ATPase p97 and its cofactor ataxin3 in health and disease: Nucleotide-induced conformational changes regulate cofactor binding","volume":"292","author":"Rao","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.str.2020.09.010","article-title":"Capturing the Conformational Ensemble of the Mixed Folded Polyglutamine Protein Ataxin-3","volume":"29","author":"Sicorello","year":"2021","journal-title":"Structure"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bpj.2018.05.029","article-title":"The Structural Properties in Solution of the Intrinsically Mixed Folded Protein Ataxin-3","volume":"115","author":"Sicorello","year":"2018","journal-title":"Biophys. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.pneurobio.2011.11.006","article-title":"Toward understanding Machado-Joseph disease","volume":"97","author":"Paulson","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1006\/nbdi.1998.0208","article-title":"Heterogeneous intracellular localization and expression of ataxin-3","volume":"5","author":"Trottier","year":"1998","journal-title":"Neurobiol. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1154203","DOI":"10.3389\/fnmol.2023.1154203","article-title":"Regional and age-dependent changes in ubiquitination in cellular and mouse models of spinocerebellar ataxia type 3","volume":"16","author":"Luo","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bbrc.2007.08.062","article-title":"Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination","volume":"362","author":"Schmitt","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1096\/fj.06-7002com","article-title":"Functional genomics and biochemical characterization of the C. elegans orthologue of the Machado-Joseph disease protein ataxin-3","volume":"21","author":"Rodrigues","year":"2007","journal-title":"FASEB J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1093\/hmg\/ddg297","article-title":"Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics","volume":"12","author":"Scheel","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1093\/hmg\/ddg344","article-title":"The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity","volume":"12","author":"Burnett","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.0407252102","article-title":"The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation","volume":"102","author":"Burnett","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","unstructured":"Maya, V.R., Kimberly, C.G., Prajakta, D.M., and Patrick, J.L. (bioRxiv, 2020). Ubiquitin Substrates Dramatically Increase Ataxin3 Deubiquitinating Activity: Allosteric crosstalk connects three distinct sites, bioRxiv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/hmg\/ddq452","article-title":"The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability","volume":"20","author":"Durcan","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11635","DOI":"10.1074\/jbc.M412042200","article-title":"Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes","volume":"280","author":"Jana","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/35050618","article-title":"The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins","volume":"3","author":"Connell","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1128\/MCB.19.6.4535","article-title":"Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions","volume":"19","author":"Ballinger","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.molcel.2011.05.036","article-title":"Ube2w and ataxin-3 coordinately regulate the ubiquitin ligase CHIP","volume":"43","author":"Scaglione","year":"2011","journal-title":"Mol. Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1128\/MCB.23.18.6469-6483.2003","article-title":"Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis","volume":"23","author":"Stenroos","year":"2003","journal-title":"Mol. Cell Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/hmg\/ddl164","article-title":"Ataxin-3 binds VCP\/p97 and regulates retrotranslocation of ERAD substrates","volume":"15","author":"Zhong","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Johnson, S.L., Libohova, K., Blount, J.R., Sujkowski, A.L., Prifti, M.V., Tsou, W.L., and Todi, S.V. (2021). Targeting the VCP-binding motif of ataxin-3 improves phenotypes in Drosophila models of Spinocerebellar Ataxia Type 3. Neurobiol. Dis., 160.","DOI":"10.1016\/j.nbd.2021.105516"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.nbd.2018.04.013","article-title":"Toxicity and aggregation of the polyglutamine disease protein, ataxin-3 is regulated by its binding to VCP\/p97 in Drosophila melanogaster","volume":"116","author":"Ristic","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1111\/febs.15617","article-title":"Alternative systems for misfolded protein clearance: Life beyond the proteasome","volume":"288","author":"Johnston","year":"2021","journal-title":"FEBS J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","article-title":"Progress towards therapies for disease modification in Parkinson\u2019s disease","volume":"20","author":"Vijiaratnam","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00415-018-9076-4","article-title":"Spinocerebellar ataxia: An update","volume":"266","author":"Sullivan","year":"2019","journal-title":"J. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/d41573-021-00088-6","article-title":"Double setback for ASO trials in Huntington disease","volume":"20","author":"Kingwell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41593-020-00778-1","article-title":"Gene-based therapies for neurodegenerative diseases","volume":"24","author":"Sun","year":"2021","journal-title":"Nat. Neurosci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","article-title":"Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD","volume":"26","author":"Kantor","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.omtn.2021.11.015","article-title":"Allele-specific targeting of mutant ataxin-3 by antisense oligonucleotides in SCA3-iPSC-derived neurons","volume":"27","author":"Hauser","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.omtm.2019.10.008","article-title":"Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease","volume":"15","author":"Martier","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s10020-023-00695-6","article-title":"Therapeutic effects of engineered exosome-based miR-25 and miR-181a treatment in spinocerebellar ataxia type 3 mice by silencing ATXN3","volume":"29","author":"Tang","year":"2023","journal-title":"Mol. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ana.26713","article-title":"Antisense Oligonucleotide Silencing Reverses Abnormal Neurochemistry in Spinocerebellar Ataxia 3 Mice","volume":"94","author":"McLoughlin","year":"2023","journal-title":"Ann. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41398-021-01605-2","article-title":"CRISPR\/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells","volume":"11","author":"He","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: Progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.neo.2023.100929","article-title":"Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma","volume":"44","author":"Han","year":"2023","journal-title":"Neoplasia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s12311-020-01150-6","article-title":"Trehalose in Machado-Joseph Disease: Safety, Tolerability, and Efficacy","volume":"19","author":"Zaltzman","year":"2020","journal-title":"Cerebellum"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Vo, S.H., Butzlaff, M., Pru, S.K., Ni Charthaigh, R.A., Karsten, P., Lankes, A., Hamm, S., Simons, M., Adryan, B., and Schulz, J.B. (2012). Large-scale screen for modifiers of ataxin-3-derived polyglutamine-induced toxicity in Drosophila. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047452"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s13311-020-00993-5","article-title":"Small Molecule Rescue of ATXN3 Toxicity in C. elegans via TFEB\/HLH-30","volume":"18","author":"Fardghassemi","year":"2021","journal-title":"Neurotherapeutics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/brain\/aww228","article-title":"Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3","volume":"139","author":"Costa","year":"2016","journal-title":"Brain"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ashraf, N.S., Sutton, J.R., Yang, Y., Ranxhi, B., Libohova, K., Shaw, E.D., Barget, A.J., Todi, S.V., Paulson, H.L., and Costa, M.D.C. (2020). Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein. Neurobiol. Dis., 137.","DOI":"10.1016\/j.nbd.2019.104697"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41598-024-51954-3","article-title":"The natural breakthrough: Phytochemicals as potent therapeutic agents against spinocerebellar ataxia type 3","volume":"14","author":"Naveed","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"113544","DOI":"10.1016\/j.expneurol.2020.113544","article-title":"Overexpression of FKH-2\/FOXG1 is neuroprotective in a C. elegans model of Machado-Joseph disease","volume":"337","author":"Fardghassemi","year":"2021","journal-title":"Exp. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"14911","DOI":"10.1038\/s41598-023-41192-4","article-title":"High throughput compound screening in neuronal cells identifies statins as activators of ataxin 3 expression","volume":"13","author":"Stahl","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0014-5793(76)80996-9","article-title":"Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity","volume":"72","author":"Endo","year":"1976","journal-title":"FEBS Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1146\/annurev-biochem-062917-011852","article-title":"Retrospective on Cholesterol Homeostasis: The Central Role of Scap","volume":"87","author":"Brown","year":"2018","journal-title":"Annu. Rev. Biochem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13024-018-0261-9","article-title":"Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model","volume":"13","author":"Toonen","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00401-019-02019-7","article-title":"Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia","volume":"138","author":"Nobrega","year":"2019","journal-title":"Acta Neuropathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"696778","DOI":"10.3389\/fnagi.2021.696778","article-title":"Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications","volume":"13","author":"Pikuleva","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1146\/annurev-biochem-081820-101010","article-title":"Posttranslational Regulation of HMG CoA Reductase, the Rate-Limiting Enzyme in Synthesis of Cholesterol","volume":"90","author":"Schumacher","year":"2021","journal-title":"Annu. Rev. Biochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/cr.2008.61","article-title":"Feedback regulation of cholesterol synthesis: Sterol-accelerated ubiquitination and degradation of HMG CoA reductase","volume":"18","year":"2008","journal-title":"Cell Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/7\/3984\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:22:53Z","timestamp":1760106173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/7\/3984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":65,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["ijms25073984"],"URL":"https:\/\/doi.org\/10.3390\/ijms25073984","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]}}}